A Single-arm, Open-label Clinical Trial to Evaluate the Effect of SMT04 in Irritable Bowel Syndrome (IBS)

Status: Recruiting
Location: See location...
Intervention Type: Dietary supplement
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

Probiotic supplements improve IBS symptoms through manipulation of the gut microbiota. Metabolites derived from microbiota metabolism and host-microbiota co-metabolism have an impact on host intracellular signalling pathways. Although probiotic supplements improve IBS symptoms, the precise composition of probiotics that can achieve optimal response remains unclear. SMT04 (M3XTRA, GenieBiome Limited, Hong Kong, China) is a novel product that is commercially available as a dietary supplement in Singapore. It consists of a patented probiotics blend of 5 probiotics (3 Bifidobacteria and 2 Streptococci with 12.5 billion CFU in 1 sachet). Probiotics preparation that included varying composition of Bifidobacteria and Streptococci strains had previously demonstrated efficacy in achieving symptom improvement in IBS patients. Streptococcus thermophilus, a component of the blended probiotics, significantly improved intestinal functional barrier in healthy subjects. Thus there is potential for SMT04, a dietary supplement, to be a treatment option for IBS patients. This is a multi-centered trial, all data and samples from the study sites will be pooled together for analysis.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 21
Maximum Age: 55
Healthy Volunteers: f
View:

• Male or female, aged from 21 years to 70 years old

• Meet the criteria of the Rome-III-definition of IBS with diarrhoea or mixed subtypes, or functional diarrhoea Rome-III-definition: Abdominal pain or abdominal discomfort on minimum of three days per month during the last three months, starting at least six months ago, and a minimum of two of the following criteria:

‣ Improvement of symptoms after defecation

⁃ Start of symptoms in association with a change in stool frequency

⁃ Start of symptoms in association with a change in stool consistency Subtype of IBS-D which requires more than 25% of the participant's stools to be loose and less than 25% hard and lumpy; subtype of IBS-M which the participant's stools must be both hard and lumpy, as well as loose in consistency at least 25% of the time. Functional diarrhoea: The experience of loose or watery stools without pain occurring in at least 75% of bowel movements for at least three months over the last six months.

• Have the latest negative colonoscopy result within five years

• Literate and can complete questionnaire

• Written informed consent is obtained

Locations
Other Locations
Singapore
Dr Daphne Ang Shih Wen
RECRUITING
Singapore
Contact Information
Primary
Chun Feng Tao
Chunfeng_Tao@cgh.com.sg
+65-64267815
Time Frame
Start Date: 2024-03-20
Estimated Completion Date: 2026-12-31
Participants
Target number of participants: 40
Treatments
Experimental: SMT04 Arm
Each subject will take 1 sachet of SMT04 daily for 3 months.
Related Therapeutic Areas
Sponsors
Collaborators: GenieBiome Limited, National University Hospital, Singapore
Leads: Changi General Hospital

This content was sourced from clinicaltrials.gov